DPMAS Therapy in Liver Disease PatientsPADSTONENCT05129904
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
An observational study of DPMAS Therapy in Liver Disease Patients, run by Nanfang Hospital, Southern Medical University at 56 sites in China.
Trial summary
Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome occurring in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main cause of cirrhosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- DPMAS Therapy in Liver Disease Patients
- What is being tested?
- Double plasma molecular absorption system
- How many people
- 1,300 participants
- Where
- 56 sitesChina
- Study dates
- 15 Sep 2021to 30 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Given the global heterogeneity of current regional diagnostic criteria for ACLF, the study enrolled a subgroup of patients with chronic liver disease (CLD) related ACLF defined by total bilirubin ≥ 12 mg/dL and INR level ≥ 1.5, which simultaneously fulfilled the diagnostic criteria recommended by Chinese and Asia-Pacific, while a considerable proportion also fulfilled the ACLF diagnostic criteria defined by European guidelines. This study population is characterized by markedly elevated bilirubin levels, making it well aligned with real-world clinical practice given that DPMAS intervention selectively targets bilirubin adsorption. Additionally, previous data have suggested that this specific patient population associated with a high rate of disease progression rate (approximately 40%) and high mortality (over 20%), further suggesting that the enrolled population is suitable for screening the optimal ACLF subgroup with favorable responses to DPMAS.
Who may be able to join
- Hospitalized patients
- Age >18 years
- Chronic liver disease regardless of the etiology
- Total bilirubin ≥ 12mg/dl and INR ≥ 1.5
Who cannot join
- With ≥ 3 organ failures (SOFA criteria);
- The pregnant;
- With severe non-hepatic disease (such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission);
- Human immunodeficiency virus (HIV) infection without treatment;
- Patients with unstable hemodynamics caused by infection or acute bleeding;
- Hospital stays <48 hours;
Show all 11Show fewer
- Diagnosis of hepatocellular carcinoma during screening period;
- For the DPMAS clusters: patients decline to receive DPMAS treatment alone or in combination with PE;
- For the SOC clusters: patients plan to receive DPMAS therapy;
- Not suitable to participate in this study judging by researchers (e.g., patients with severe advanced pancreatic tumors, hematological tumors);
- Not sign the informed consent.
Trial locations and contacts
56 sites in 1 country.
56 sites in 1 country
China56 sites
Beijing Ditan Hospital, Capital Medical University
Beijing
Beijing Youan Hospital, Capital Medical University
Beijing
Luhe Hospital, Capital Medical University
Beijing
Peking University People's Hospital
Beijing
The First Hospital of Jilin University
Changchun, Jilin
Hunan Provincial People's Hospital
Changsha, Hunan
Xiangya Hospital of Central South University
Changsha, Hunan
The Second Xiangya Hospital, Central South University
Changsha
Sichuan Provincial People's Hospital
Chengdu, Sichuan
West China Hospital of Sichuan University
Chengdu, Sichuan
Chengdu Public Health Clinical Center
Chengdu
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality
Southwest Hospital, Third Military Medical University
Chongqing
The First People's Hospital of Foshan
Foshan
First Affiliated Hospital of Fujian Medical University
Fujian
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fujian
The First Affiliated Hospital of Guangxi Medical University
Guangxi
The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine
Guangxi
The People's Hospital of Guangxi Zhuang Autonomous Region
Guangxi
The Second Affiliated Hospital of Guangxi Medical University
Guangxi
Nanfang Hospital
Guangzhou, Guangdong, 510515
Guizhou Provincial People's Hospital
Guizhou
The Affiliated Hospital of Guizhou Medical University
Guizhou
The Affiliated Hospital of Zunyi Medical University
Guizhou
Hainan Provincial People's Hospital
Hainan
The Third Hospital of Hebei Medical University
Hebei, Hebei
The Second Hospital of Hebei Medical University
Hebei
First Affiliated Hospital of Anhui Medical University
Hefei
Henan Provincial People's Hospital
Henan
Taihe Hospital, Hubei University of Medicine
Hubei
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hubei
Qilu Hospital of Shandong University
Jinan, Shandong
Shandong Provincial Clinical Center for Public Health
Jinan, Shandong
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong
The Second Hospital of Shandong University
Jinan, Shandong
The First Hospital of Yunnan Province
Kunming, Yunnan
The Second Affiliated Hospital of Kunming Medical University
Kunming
The First Hospital of Lanzhou University
Lanzhou
Zhengzhou University Affiliated Luoyang Centre Hospital
Luoyang
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi
The Second Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi
Infectious Diseases Hospital Affiliated to Nanchang University
Nanchang
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu
General Hospital of Ningxia Medical University
Qinghai
Huashan Hospital, Fudan University
Shanghai
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Shanghai
Shanghai Public Health Clinical Centre, Fudan University
Shanghai
Shanghai Public Health Clinical Centre
Shanghai
The First Affiliated Hospital of Shanxi Medical University
Shanxi
Tianjin Third Central Hospital
Tianjin
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an
The First Affiliated Hospital of Xinjiang Medical University
Xinjiang
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu
The First Affiliated Hospital, Zhejiang University School of Medicine
Zhejiang
The First Affiliated Hospital of Zhengzhou University
Zhengzhou
About this study
Official title: Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint: a Multicenter, Cluster-controlled Study (PADSTONE Study)
Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome occurring in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main cause of cirrhosis. HBV related ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.) and confers with high risk of short-term mortality. For the treatment of ACLF patients, recent studies have explored the therapeutic efficacy of extracorporeal liver support therapies, such as albumin dialysis, plasma exchange. However, the clinical efficacy remains to be fully elucidated. Liver transplantation is the most efficient way to improve the survival of ACLF patients, especially for those suffering from three or more organ failures.
Recently, a novel extracorporeal system which is called double plasma molecular adsorption system (DPMAS) has been applied for the treatment of ACLF patients. DPMAS is an extracorporeal therapeutic procedure that combines two hemoperfusion devices. During treatment, toxic plasma is isolated and purified via perfusion through two adsorbers, after which the purified plasma is reinfused back into the patient's circulation. This technique requires no massive plasma supply and avoids the risks of plasma-related allergic reactions and pathogen transmission. DPMAS can rapidly alleviate jaundice and lower serum bilirubin levels, thereby mitigating the hepatotoxic effects induced by excessive bilirubin and bile acids. Despite the widespread clinical application of DPMAS in patients with liver failure, high-quality evidence supporting its definite clinical efficacy remains insufficient.
Accordingly, this prospective, multicenter cluster-controlled study is designed to evaluate the clinical benefits of DPMAS via validated hard clinical endpoints, including short-term mortality and disease progression, and screen out suitable candidate patients. Furthermore, biological specimens including plasma, urine and feces will be collected to characterize the molecular profiles of ACLF patients receiving DPMAS treatment through multi-omics analyses.
- Conditions
- DPMAS Therapy in Liver Disease Patients
- Being tested
- Double plasma molecular absorption system
- Keywords
- double plasma molecular absorption system, liver disease, acute-on-chronic liver failure, mortality
- Medical subject headings
- Liver Diseases, Acute-On-Chronic Liver Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Double plasma molecular absorption systemOther
Also called DPMAS treatment
As a type of ECLS, double plasma molecular adsorption system (DPMAS) integrates plasma filtration with two specific adsorption membranes, which can efficiently remove bilirubin and the middle-molecular toxins, respectively. In the DPMAS clusters, patients receive at least one DPMAS treatment session during the study period, as treatment details regarding the number of DPMAS sessions and session intervals are made upon institutional protocols. DPMAS treatment can be applied either alone or in combination with PE, and both modalities are permitted in this study. PE is allowed in both groups as standard supportive care.
| Study group | Role | What they receive |
|---|---|---|
| Double plasma molecular absorption system treatment | Patients in DPMAS clusters receive at least one DPMAS treatment session (with or without plasma exchange) in this study. Receives: Other: Double plasma molecular absorption system | |
| Standard of care | Patients in the SOC clusters receive routine treatments other than DPMAS, in accordance with established clinical guidelines for the management of ACLF |
What is being measured
The primary outcome is the main question the study is designed to answer.
The rate of progression within 4 weeks
The progression of ACLF within 4 weeks
Measured: 4 weeks
The 4-week transplant-free mortality
The 4-week transplant-free mortality
Measured: 4 weeks
Secondary outcomes (2)
The transplant-free mortality within 12 weeks
The transplant-free mortality within 12 weeks
Measured: 12 weeks
The progression of ACLF within 12 weeks
The progression rate of ACLF within 12 weeks
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Nov 2021
- Study start15 Sep 2021
- Primary completion30 Dec 2024
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DPMAS Therapy in Liver Disease PatientsStudies of the same condition, open and under way.
- More trials run by Nanfang Hospital, Southern Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- The First Affiliated Hospital of Nanchang University, Tianjin Third Central Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, The First Affiliated Hospital of Anhui Medical University, West China Hospital, The Second Affiliated Hospital of Kunming Medical University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, The Second Affiliated Hospital of Chongqing Medical University, First Affiliated Hospital of Zhejiang University, The Ninth Hospital of Nanchang, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Shanxi Medical University, Taihe Hospital, Shanghai Public Health Clinical Center of Fudan University, First Affiliated Hospital Xi'an Jiaotong University, Southwest Hospital, China, Qilu Hospital of Shandong University, Beijing Ditan Hospital, First Affiliated Hospital of Guangxi Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shandong Provincial Hospital, Sichuan Provincial People's Hospital, Huashan Hospital, People's Hospital of Anshun City of Guizhou Province, LanZhou University, General Hospital of Ningxia Medical University, Second Xiangya Hospital of Central South University, Chengdu Public Health Clinical Center, Ruijin Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shandong First Medical University, The Second Hospital of Shandong University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Xuzhou Medical University, Hunan Provincial People's Hospital, Zhengzhou University Affiliated Luoyang Centre Hospital, Hebei Medical University Third Hospital, The Second Hospital of Hebei Medical University, Hainan People's Hospital, Zunyi Medical College, The Affiliated Hospital Of Guizhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, People's Hospital of Guangxi Zhuang Autonomous Region, First People's Hospital of Foshan, First Affiliated Hospital of Fujian Medical University, Capital Medical University, Peking University People's Hospital, Xiangya Hospital of Central South University, Shanghai Public Health Clinical Centre, The First Hospital of Jilin University, The First Hospital of Yunnan Province, Shandong Provincial Clinical Center for Public Health, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Responsible party
- Sponsor
- Investigators
- Jinjun Chen, Doctor, Study director, Nanfang Hospital, Sourthern Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05129904
- Sponsor's protocol ID
- NFEC-2021-259
- Acronym
- PADSTONE
- Status last verified
- May 2026
- First submitted
- 31 Oct 2021
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint: a Multicenter, Cluster-controlled Study (PADSTONE Study)
- ClinicalTrials.gov ID
- NCT05129904
- Acronym / sponsor ID
- PADSTONE / NFEC-2021-259
- Conditions
- DPMAS Therapy in Liver Disease Patients
- Keywords
- double plasma molecular absorption system, liver disease, acute-on-chronic liver failure, mortality
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,300 participants (estimated)
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityUniversity, hospital or other
- Collaborators
- The First Affiliated Hospital of Nanchang University, Tianjin Third Central Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, The First Affiliated Hospital of Anhui Medical University, West China Hospital, The Second Affiliated Hospital of Kunming Medical University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, The Second Affiliated Hospital of Chongqing Medical University, First Affiliated Hospital of Zhejiang University, The Ninth Hospital of Nanchang, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Shanxi Medical University, Taihe Hospital, Shanghai Public Health Clinical Center of Fudan University, First Affiliated Hospital Xi'an Jiaotong University, Southwest Hospital, China, Qilu Hospital of Shandong University, Beijing Ditan Hospital, First Affiliated Hospital of Guangxi Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shandong Provincial Hospital, Sichuan Provincial People's Hospital, Huashan Hospital, People's Hospital of Anshun City of Guizhou Province, LanZhou University, General Hospital of Ningxia Medical University, Second Xiangya Hospital of Central South University, Chengdu Public Health Clinical Center, Ruijin Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shandong First Medical University, The Second Hospital of Shandong University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Xuzhou Medical University, Hunan Provincial People's Hospital, Zhengzhou University Affiliated Luoyang Centre Hospital, Hebei Medical University Third Hospital, The Second Hospital of Hebei Medical University, Hainan People's Hospital, Zunyi Medical College, The Affiliated Hospital Of Guizhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, People's Hospital of Guangxi Zhuang Autonomous Region, First People's Hospital of Foshan, First Affiliated Hospital of Fujian Medical University, Capital Medical University, Peking University People's Hospital, Xiangya Hospital of Central South University, Shanghai Public Health Clinical Centre, The First Hospital of Jilin University, The First Hospital of Yunnan Province, Shandong Provincial Clinical Center for Public Health, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Study start
- 15 Sep 2021 (actual)
- Primary completion
- 30 Dec 2024 (actual)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 22 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome occurring in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main cause of cirrhosis. HBV related ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.) and confers with high risk of short-term mortality. For the treatment of ACLF patients, recent studies have explored the therapeutic efficacy of extracorporeal liver support therapies, such as albumin dialysis, plasma exchange. However, the clinical efficacy remains to be fully elucidated. Liver transplantation is the most efficient way to improve the survival of ACLF patients, especially for those suffering from three or more organ failures.
Recently, a novel extracorporeal system which is called double plasma molecular adsorption system (DPMAS) has been applied for the treatment of ACLF patients. DPMAS is an extracorporeal therapeutic procedure that combines two hemoperfusion devices. During treatment, toxic plasma is isolated and purified via perfusion through two adsorbers, after which the purified plasma is reinfused back into the patient's circulation. This technique requires no massive plasma supply and avoids the risks of plasma-related allergic reactions and pathogen transmission. DPMAS can rapidly alleviate jaundice and lower serum bilirubin levels, thereby mitigating the hepatotoxic effects induced by excessive bilirubin and bile acids. Despite the widespread clinical application of DPMAS in patients with liver failure, high-quality evidence supporting its definite clinical efficacy remains insufficient.
Accordingly, this prospective, multicenter cluster-controlled study is designed to evaluate the clinical benefits of DPMAS via validated hard clinical endpoints, including short-term mortality and disease progression, and screen out suitable candidate patients. Furthermore, biological specimens including plasma, urine and feces will be collected to characterize the molecular profiles of ACLF patients receiving DPMAS treatment through multi-omics analyses.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Double plasma molecular absorption system treatment | – | Other: Double plasma molecular absorption systemPatients in DPMAS clusters receive at least one DPMAS treatment session (with or without plasma exchange) in this study. |
| Standard of care | – | –Patients in the SOC clusters receive routine treatments other than DPMAS, in accordance with established clinical guidelines for the management of ACLF |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Given the global heterogeneity of current regional diagnostic criteria for ACLF, the study enrolled a subgroup of patients with chronic liver disease (CLD) related ACLF defined by total bilirubin ≥ 12 mg/dL and INR level ≥ 1.5, which simultaneously fulfilled the diagnostic criteria recommended by Chinese and Asia-Pacific, while a considerable proportion also fulfilled the ACLF diagnostic criteria defined by European guidelines. This study population is characterized by markedly elevated bilirubin levels, making it well aligned with real-world clinical practice given that DPMAS intervention selectively targets bilirubin adsorption. Additionally, previous data have suggested that this specific patient population associated with a high rate of disease progression rate (approximately 40%) and high mortality (over 20%), further suggesting that the enrolled population is suitable for screening the optimal ACLF subgroup with favorable responses to DPMAS.
Key inclusion criteria (4 listed)
- Hospitalized patients
- Age >18 years
- Chronic liver disease regardless of the etiology
- Total bilirubin ≥ 12mg/dl and INR ≥ 1.5
Key exclusion criteria (11 listed)
- With ≥ 3 organ failures (SOFA criteria);
- The pregnant;
- With severe non-hepatic disease (such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission);
- Human immunodeficiency virus (HIV) infection without treatment;
- Patients with unstable hemodynamics caused by infection or acute bleeding;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Double plasma molecular absorption systemAlso: DPMAS treatmentAs a type of ECLS, double plasma molecular adsorption system (DPMAS) integrates plasma filtration with two specific adsorption membranes, which can efficiently remove bilirubin and the middle-molecular toxins, respectively. In the DPMAS clusters, patients receive at least one DPMAS treatment session during the study period, as treatment details regarding the number of DPMAS sessions and session intervals are made upon institutional protocols. DPMAS treatment can be applied either alone or in combination with PE, and both modalities are permitted in this study. PE is allowed in both groups as standard supportive care. | Other | Double plasma molecular absorption system treatment |
Primary outcome
The rate of progression within 4 weeks
Time frame: 4 weeks
The progression of ACLF within 4 weeks
The 4-week transplant-free mortality
Time frame: 4 weeks
The 4-week transplant-free mortality
2 secondary outcomes
The transplant-free mortality within 12 weeks
Time frame: 12 weeks
The progression of ACLF within 12 weeks
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
- Individual participant dataSharing planned: No
Related trials for DPMAS Therapy in Liver Disease Patients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jinjun Chen, Doctor study director
Nanfang Hospital, Sourthern Medical University
56 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of DPMAS Therapy in Liver Disease Patients, run by Nanfang Hospital, Southern Medical University at 56 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 56 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The rate of progression within 4 weeks (time frame: 4 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.